课题基金 / 基金详情

IMMUNOTHERAPY OF PSORIASIS--MECHANISM OF DAB 389

IMMUNOTHERAPY OF PSORIASIS--MECHANISM OF DAB 389
银屑病的免疫治疗--DAB 389的作用机制
批准号:
6051472
负责人:
JAMES G KRUEGER
金额:
$4.34万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
1996
资助国家:
美国
项目状态:
已结题
起止时间:
1996-04-01 至 2001-03-31

项目摘要

项目成果

JAMES G KRUEGER的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Psoriasis vulgaris is a human inflammatory skin disorder characterized by tissue infiltration with IL-2R+ lymphocytes and marked epidermal changes. We propose that psoriasis is a primary immune-mediated disorder, as clinical and pathological disease features can be reversed by treatment with DAB389IL-2, a novel fusion toxin which reacts only with cells expressing high affinity IL-2R. Our major hypothesis is that psoriasis is an autoimmune disease that is caused by a response of epidermal keratinocytes to lL-2R+ tissue infiltrating leukocytes, most probably CD8+CD25+TIA-1+ cytotoxic effectors, cells that we have identified in large numbers in diseased epidermis. The specific aims of this proposal are: 1. To establish the specific ability of DAB389IL-2 to delete T-lymphocytes bearing lL-2 receptors from diseased tissue and to correlate changes in tissue-infiltrating leukocytes with quantitative and qualitative alterations in other cellular features of psoriatic pathology. 2. To determine changes in the activational and functional state of cutaneous leukocytes during treatment with DAB389IL-2. 3. To determine the effect of DAB-lL-2 therapy on the number and function of lL-2 reactive T cells that can be cloned from skin biopsies. Using a series of validated markers to quantify the extent of clinical disease, we propose to relate therapeutic improvements to number, function, and activation state of specific leukocyte subsets in psoriatic tissue. We will employ sensitive immunohistochemical approaches on cryostat-prepared tissue sections, and we will assess functional activation of disease-related leukocytes through a new technique that allows us to recover viable leukocytes from psoriatic tissues. We will establish whether DAB389IL-2 depletes effector CD8+ lymphocytes from psoriatic tissues, and/or whether this agent acts on antigen presenting dendritic cells or CD4+ lymphocytes. The possibility that DAB389IL-2 alters production of inflammatory cytokines and immunoregulatory cytokines will be explored by cloning and analysis of disease-associated T- lymphocytes before and after therapy by limiting dilution approaches. The study of psoriasis as a model autoimmune disease is advantageous because (1) psoriasis is the most common human autoimmune disorder, affecting 2-3% of the population, (2) disease activity in psoriasis vulgaris is relatively stable, allowing for study of relatively small patient populations to establish significance of outcomes, (3) clinical disease activity is visible and can be quantified by validated measures and non-invasive imaging, (4) lesional and non-lesional tissue is readily available for comparative laboratory studies, (5) target epithelial cells can be readily cultured in vitro to examine interactions with effector leukocytes or immune-derived cytokines, and (6) enriched, functional populations of tissue-infiltrating leukocytes can be obtained for direct study by a novel organ culture system.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
PHARMACODYNAMIC EFFECTS OF CYCLOSPORINE A IN MODERATE-SEVERE PSORIASIS
  • 批准号:
    7206998
  • 项目类别:
  • 资助金额:
    $0.03万
  • 财政年份:
    2005
  • 负责人:
    JAMES G KRUEGER
  • 依托单位:
SKIN BIOPSY FOR ANALYSIS OF CELL GROWTH, CELL DIFFERENTIATION AND INFLAMMATION
  • 批准号:
    7207013
  • 项目类别:
  • 资助金额:
    $0.03万
  • 财政年份:
    2005
  • 负责人:
    JAMES G KRUEGER
  • 依托单位:
NATURAL COURSE & HISTORY OF PSORIASIS BEFORE, DURING AND AFTER TREATMENT
  • 批准号:
    7207001
  • 项目类别:
  • 资助金额:
    $21.79万
  • 财政年份:
    2005
  • 负责人:
    JAMES G KRUEGER
  • 依托单位:
COLLECTION OF BLOOD SPECIMENS FOR RESEARCH PURPOSES
  • 批准号:
    7206995
  • 项目类别:
  • 资助金额:
    $2.94万
  • 财政年份:
    2005
  • 负责人:
    JAMES G KRUEGER
  • 依托单位:
海外基金